Lucence Receives CLIA Certification for US Laboratory, Expands Access to Amplicon-Based Liquid Biopsy Tests

PALO ALTO, Calif.--(BUSINESS WIRE)--Molecular diagnostics company Lucence today announced that the company’s Palo Alto laboratory received certification from the U.S. Department of Health and Human Services’ Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. With this accreditation, Lucence will rapidly scale United States-based testing capacity for its flagship liquid biopsy blood test, LiquidHALLMARK®, furthering the Company

Click to view original post